Trial Profile

Optimization of Treatment and Management of Schizophrenia in Europe

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amisulpride (Primary) ; Clozapine (Primary) ; Olanzapine (Primary)
Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
Focus Therapeutic Use
Acronyms OPTiMiSE; OPTiMiSE1; OPTiMiSE2; OPTiMiSE2a; OPTiMiSE3

Most Recent Events

29 Mar 2023 Results published in the Journal of Clinical Psychiatry
01 Jul 2021 Results (N=387) assessing the relationship between serum NMDAR antibodies and 1) symptom profile at presentation and 2) response to antipsychotic treatment in a large cohort of patients with first episode psychosis (FEP) published in the Biological Psychiatry
01 May 2021 Status changed from recruiting to completed, according to Results published in the Schizophrenia Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com